|
Press Releases |
|
|
|
Tuesday, July 16, 2024 |
|
エーザイ、ホスラブコナゾールのアジア・オセアニアにおけるライセンス契約を佐藤製薬と締結 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、抗真菌剤ホスラブコナゾールについて、真菌性疾患に対するアジア・オセアニアにおける開発および商業化に関するライセンス契約を佐藤製薬株式会社(本社:東京都、以下 佐藤製薬)と締結したことをお知らせします。 more info >> |
|
Friday, July 12, 2024 |
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
エーザイとバイオジェン、「レケンビ」(レカネマブ)がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)と バイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、 CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、ヒト化抗ヒト可溶性アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ®」(一般名:レカネマブ)について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
Thursday, July 11, 2024 |
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
エーザイとバイオジェン、「LEQEMBI」(レカネマブ)が香港においてアルツハイマー病治療剤として承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)と バイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、 CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、ヒト化抗ヒト可溶性 アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ(R)」(香港製品名:「樂意保(R)」、一般名:レカネマブ)について、香港衛生署(Department of Health)より新薬承認を取得したことをお知らせします。 more info >> |
|
Tuesday, July 2, 2024 |
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
Friday, June 28, 2024 |
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
Friday, June 21, 2024 |
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
Monday, June 10, 2024 |
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
エーザイとバイオジェン、早期アルツハイマー病治療剤「レケンビ(R)」の静注維持投与に関する生物製剤承認一部変更申請が米国FDAにより受理 |
エーザイ株式会社とバイオジェン・インクは、このたび、ヒト化抗ヒト可溶性アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ(R)」(一般名:レカネマブ)について、静注(IV)維持投与に関する生物製剤承認一部変更申請(sBLA)が米国食品医薬品局(FDA)に受理されたことをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
為自己選擇合適的信用卡
Sept 21, 2024 00:00 HKT/SGT
|
|
|
为自己选择合适的信用卡
Sept 21, 2024 00:00 HKT/SGT
|
|
|
Selecting the Right Credit Card for Yourself
Sept 21, 2024 00:00 HKT/SGT
|
|
|
Elastos Creates World's First live Music Inscription on Bitcoin at Token 2049
Sept 20, 2024 22:00: JST
|
|
|
Elastos Creates World's First live Music Inscription on Bitcoin at Token 2049
Sept 20, 2024 22:00 HKT/SGT
|
|
|
华邦科技成立「大湾区永续发展研究院」
Sept 20, 2024 19:05 HKT/SGT
|
|
|
華邦科技成立「大灣區永續發展研究院」
Sept 20, 2024 18:34 HKT/SGT
|
|
|
Mitsubishi Corporation, KDDI CORPORATION, Lawson, Inc. Launching an Initiative to Transform into "Next-generation Convenience Store"
Sept 20, 2024 18:02 JST
|
|
|
Hitachi Rail is innovating and delivering transformative 5G digital signalling
Sept 20, 2024 16:47 JST
|
|
|
Seoul Metropolitan Government Intensifies Efforts to Become a Global Top 5 City by Attracting Singaporean Companies
Sept 20, 2024 14:00: JST
|
|
|
Olympus Launches New 4K Camera Head for Urological Endoscopy
Sept 20, 2024 15:00 JST
|
|
|
Seoul Metropolitan Government Intensifies Efforts to Become a Global Top 5 City by Attracting Singaporean Companies
Sept 20, 2024 13:00 HKT/SGT
|
|
|
Ching Lee Holdings (3728. HK) holds quality-driven strategies to acquire market share
Sept 20, 2024 12:27 HKT/SGT
|
|
|
正利工程以质取胜 争夺巿场份额
Sept 20, 2024 11:58 HKT/SGT
|
|
|
正利工程以質取勝 爭奪市場份額
Sept 20, 2024 11:38 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|